The management of unresectable hepatocellular carcinoma (HCC) involves recognizing and managing adverse events and effectively working with a multidisciplinary team. This Clinical ForumSM brings together an interventional radiologist, oncologist, and hepatologist to discuss how they work together at their institutions to achieve a common goal.
This activity is designed to meet the educational needs of oncology providers, including physicians, nurse practitioners, and physician assistants who manage patients with hepatocellular carcinoma (HCC).
Educational Objectives
Upon completion of this activity, participants should be better able to:
Identify and manage adverse events associated with both targeted therapy and immune checkpoint inhibitors
Incorporate a multidisciplinary approach to the management of advanced hepatocellular carcinoma (HCC)
Activity Faculty
Ghassan K. Abou-Alfa, MD, MBA (Chair)
Professor
Memorial Sloan Kettering Cancer Center
New York, NY
Anne M. Covey, MD
Radiologist
Memorial Hospital for Cancer and Allied Diseases
New York, NY
Amit Singal, MD, MS
David Bruton Jr. Professor in Clinical Cancer Research Associate Professor, Medicine Medical Director, Liver Tumor Program Clinical Chief, Hepatology
University of Texas Southwestern
Dallas, TX